Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies
Matthias E. Liechti, Franz X. Vollenweider
Human Psychopharmacology Clinical and Experimental December 1, 2001 DOI: 10.1002/hup.348 via OpenAlex
Summary
AI-generated from the abstractThe psychological effects of MDMA (Ecstasy) largely depend on the release of serotonin (5-HT), while its stimulant-like euphoric mood effects relate in part to dopamine D2 receptor stimulation, and its mild hallucinogen-like perceptual effects are due to serotonergic 5-HT2 receptor stimulation. In 44 healthy volunteers, the selective serotonin reuptake inhibitor citalopram markedly reduced most subjective effects of MDMA, including positive mood, extraversion, and self-confidence, and also attenuated cardiovascular and adverse effects. The D2 antagonist haloperidol selectively reduced MDMA-induced positive mood but had no effect on other subjective or cardiovascular responses. The 5-HT2 antagonist ketanserin selectively reduced MDMA-induced perceptual changes and emotional excitation.
Study at a glance
| Characteristics | Double-blind placebo-controlled within-subject study Peer reviewed |
|---|---|
| Sample size | 44 |
| Population | Healthy human volunteers |
| Topics | MDMA Serotonin |
| Keywords | Ketanserin Citalopram Hallucinogen |
| Citations | 243 |
| Key finding | The overall psychological effects of MDMA depend largely on carrier-mediated 5-HT release, while its euphoric mood effects relate in part to dopamine D2 receptor stimulation and its perceptual effects to 5-HT2 receptor stimulation. |
Abstract
Abstract In preclinical studies, 3,4‐methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) has been shown to release serotonin (5‐HT), dopamine and norepinephrine. However, the role of these neurotransmitters and their corresponding receptor sites in mediating the subjective effects of MDMA has not yet been studied in humans. Therefore, we investigated the effects of three different neuroreceptor pretreatments on the subjective, cardiovascular and adverse effects of MDMA (1.5 mg/kg orally) in 44 healthy human volunteers. Pretreatments were: the selective serotonin reuptake inhibitor citalopram (40 mg intravenously) in 16 subjects, the 5‐HT 2 antagonist ketanserin (50 mg orally) in 14 subjects, and the D 2 antagonist haloperidol (1.4 mg intravenously) in 14 subjects. Each of these studies used a double‐blind placebo‐controlled within‐subject design and all subjects were examined under placebo, pretreatment, MDMA and pretreatment plus MDMA conditions. Citalopram markedly reduced most of the subjective effects of MDMA, including positive mood, increased extraversion and self‐confidence. Cardiovascular and adverse effects of MDMA were also attenuated by citalopram. Haloperidol selectively reduced MDMA‐induced positive mood but had no effect on other subjective effects of MDMA or the cardiovascular or adverse responses to MDMA. Ketanserin selectively reduced MDMA‐induced perceptual changes and emotional excitation. These results indicate that the overall psychological effects of MDMA largely depend on carrier‐mediated 5‐HT release, while the more stimulant‐like euphoric mood effects of MDMA appear to relate, at least in part, to dopamine D 2 receptor stimulation. The mild hallucinogen‐like perceptual effects of MDMA appear to be due to serotonergic 5‐HT 2 receptor stimulation. Copyright © 2001 John Wiley & Sons, Ltd.